Connect with us
Prague Gaming & TECH Summit 2024

Fintech PR

CBD Oil For Anxiety: Health Canal 2020 Update

Published

on

 

CBD is gaining attention in the medicine industry because of its promising health benefits, including the many anecdotal evidence that state its potential health benefit to various illnesses. Due to that, more scientists and medical professionals have started their hands in studying the effects of CBD for different health concerns.

According to the Healthcanal.com, cannabidiol has been shown to mitigate stress in certain animals, such as rats. It was observed that the study subjects manifested lower behavioral signs of anxiety. In addition to that, the physiological symptoms they exhibited like increased heart rate were also improved. More so, it’s important to note that these studies are applicable only to generalized types of anxiety, which the study subjects were placed under.

When it comes to other types of this condition, such as post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and even anxiety-induced insomnia, CBD has also shown positive impacts. In fact, a 2011 study revealed that people with social anxiety disorder who were subjects of the said study had reduced anxiety levels after they were administered with 400 milligrams of CBD.

Furthermore, other studies also show how CBD can help with people with PTSD, especially those who experienced nightmares and who had tendencies to replay negative memories.

Does CBD Oil help anxiety?

Yes, it helps although more studies are still needed in order to gain confirmation from the medical community. However, there is a published study from Permanente Journal that says that 79% of the study participants manifested reduced anxiety all the more that there are additional studies that prove CBD’s encouraging potential as a treatment. The results have already made mental health advocates hopeful enough in considering CBD as a treatment for anxiety, which has long been a concern for people who are suffering from it.

Despite the continuous reminder set forth by the medical experts to not fully depend on one’s treatment of CBD, there are still many people who cling onto its potential. In fact, a 2019 Gallup Poll revealed that 14% of the Americans use CBD. Another poll also shows that 37% of CBD users utilize CBD for anxiety with several of these participants noting its effectiveness.

Of course, CBD’s value cannot be diminished in spite of the many cautions the medical experts have provided because CBD users find it as a holistic treatment to manage anxiety that does not cause harmful side effects. CBD does it differently as it utilizes the natural interaction of CBD and the human body through the endocannabinoid system, which is responsible for self-regulation and mood changes.

How the endocannabinoid system works has to do with human bodies producing endocannabinoids everyday, which then bind to the receptors found all over human bodies. Examples of these receptors are CB1 and CB2 receptors, which are typically found in the peripheral nervous system and central nervous system.

It works for anxiety disorders and other neurological disorders since it is also anti-inflammatory and antibacterial, according to Joseph Cohen who is a cannabis doctor from Boulder, Colorado.

CBD Dosage for Anxiety

First and foremost, for people who are interested in taking CBD, they should talk to their doctors. Doctor is the best person who can prescribe the appropriate dosage for one’s body capacity.

Other than that, it’s worth mentioning that taking CBD does not have a universal dosage for everyone. The dosage entirely depends on how much one body can tolerate, hence it is suggested  to seek for doctors’ opinions.

Nevertheless, the National Organization for the Reform of Marijuana Laws (NORML) cautions that people have to choose a reliable CBD outlet that is honest enough when it comes to providing the CBD amount that matches what’s stated on their product labels. There are many outlets that claim to be tested by a third-party laboratory, so people need to make sure that the CBD outlet they‘re checking in has proofs that reveal authentic lab results.

Why does it matter? The non-profit organization says that the majority of the commercial CBD products do not contain sufficient CBD that replicate the therapeutic effects found in the clinical trials.

When it comes to dosage used in CBD studies, it’s significant to mention that a 2018 study where male subjects received CBD dose before participating in a simulated public speaking test had implied how much CBD can possibly be administered to reduce anxiety levels. In the study, the researchers found that a dosage of 300 milligrams, administered orally to the study participants 90 minutes before the simulated public speaking test had reduced their feelings of being anxious. To find more significance on the study, the members of the placebo group who received only 150 milligrams had little to no benefits.

The study is a great indicator on what dosage can potentially help with such a condition, but since it covered only 57 subjects, more pieces of research are still needed to determine the right dosage for individuals who suffer from it.

Of course, that also does not mean that people should reach that level since they also need to seek for doctors’ opinions. But again, people still need to talk to their doctors for the most appropriate dosage to avoid unnecessary side effects brought by high dosage of CBD.

SOURCE Health Canal

Fintech PR

Announcement of change in the total number of votes in AB SKF

Published

on

announcement-of-change-in-the-total-number-of-votes-in-ab-skf

GOTHENBURG, Sweden, March 28, 2024 /PRNewswire/ — Due to a conversion of shares from Series A to Series B in accordance with AB SKF’s Articles of Association, the Company confirms the following.

As per 28 March 2024, the Company’s share capital amounts to SEK 1,138,377,670 and the total number of shares amounts to 29,286,933 shares of Series A and 426,064,135 shares of Series B. The number of votes in the Company amounts to 71,893,346.5.

AB SKF does not hold any own shares.

Aktiebolaget SKF
      (publ)

Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on 28 March 2024 at 08.00 CET.

CONTACT:

For further information, please contact:
PRESS: Carl Bjernstam, Head of Media Relations
tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail: [email protected] 

INVESTOR RELATIONS: Sophie Arnius, Head of Investor Relations
tel: 46 31-337 8072; mobile: 46 705-908 072; [email protected]  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/announcement-of-change-in-the-total-number-of-votes-in-ab-skf,c3953982

The following files are available for download:

https://mb.cision.com/Main/637/3953982/2702083.pdf

20240328 Announcement of change in the total number of votes in AB SKF

 

View original content:https://www.prnewswire.co.uk/news-releases/announcement-of-change-in-the-total-number-of-votes-in-ab-skf-302102292.html

Continue Reading

Fintech PR

Tetragon Financial Group Limited February 2024 Monthly Factsheet

Published

on

tetragon-financial-group-limited-february-2024-monthly-factsheet

LONDON, March 28, 2024 /PRNewswire/ — Tetragon has released its Monthly Factsheet for February 2024.

–  Net Asset Value: $ 2,801m
–  Fully Diluted NAV Per Share: $30.93
–  Share Price (TFG NA): $9.60
–  Monthly NAV per share total return: 0.7%
–  Monthly Return on Equity: 0.8%
–  Most recent quarterly dividend: $0.11
–  Dividend yield: 4.6%

Please refer to important disclosures on page three of the Monthly Factsheet.

Please click below to access the Monthly Factsheet.

February 2024 Factsheet 

About Tetragon:

Tetragon is a Guernsey closed-ended investment company. Its non-voting shares are listed on Euronext in Amsterdam, a regulated market of Euronext Amsterdam N.V., and also traded on the Specialist Fund Segment of the Main Market of the London Stock Exchange. Our investment manager is Tetragon Financial Management LP. Find out more at www.tetragoninv.com.

Tetragon’s non-voting shares are subject to restrictions on ownership by U.S. persons and are not intended for European retail investors.

Please see: https://www.tetragoninv.com/shareholders/additional-information.

Tetragon Investor Relations:
Yuko Thomas
[email protected]

Press Inquiries:
Prosek Partners
[email protected]
U.K. +44 20 3890 9193
U.S. +1 212 279 3115

This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Financial Markets Supervision Act as a collective investment scheme from a designated country.    

 

View original content:https://www.prnewswire.co.uk/news-releases/tetragon-financial-group-limited-february-2024-monthly-factsheet-302101163.html

Continue Reading

Fintech PR

XRP Healthcare move forward as one entity for African M&A venture

Published

on

xrp-healthcare-move-forward-as-one-entity-for-african-m&a-venture

DUBAI, UAE, March 28, 2024 /PRNewswire/ — In a bold move to address the challenges of the highly fragmented African healthcare sector, XRP Healthcare is excited to announce the incorporation of XRP Healthcare Africa, in Uganda. This strategic decision marks a significant step towards consolidating healthcare services and streamlining operations across the continent, fostering a more unified and efficient healthcare landscape.

 

XRP Healthcare recognizing the critical need for an integrated healthcare system, has taken decisive action by establishing XRP Healthcare Africa, in Uganda – a fully autonomous entity with a compliant legal structure to operate on the African continent.

This development is a testament to XRP Healthcare’s commitment to creating a sustainable and independent operational framework in Uganda and Africa.

“Our vision for XRP Healthcare Africa is to create a robust and unified healthcare entity that can efficiently address the needs of the African population,” stated CEO/Founder Kain Roomes at XRP Healthcare. “By consolidating our mergers and acquisitions local operations under XRP Healthcare Africa, we are eliminating dependencies on third-party entities such as The Burnratty Investment Group, which will no longer be part of our plans moving forward, but rather we have opted for a fully owned entity such as XRP Healthcare Africa, ensuring a streamlined and cohesive approach towards achieving our M&A goals here in Uganda.”

The Dubai-incorporated arm of XRP Healthcare, established last year in the UAE, will be pivotal in facilitating the organization’s acquisitions across the continent. Additionally, the recent incorporation of XRP Healthcare Africa in Uganda signifies a strategic move to enhance the company’s ability to manage local transactions and operations efficiently, further solidifying its presence and commitment to improving healthcare in Africa.

“Setting up XRP Healthcare Africa in Uganda is a critical step in our strategy to deepen our engagement with local communities,” explained Laban Roomes, Business Development Officer at XRP Healthcare. “This local incorporation allows us to navigate the unique challenges and opportunities within the African healthcare sector more effectively, ensuring that our efforts are closely aligned with the needs of the communities we serve.”

Over the coming weeks and months, XRP Healthcare is poised to share updates and progress on its journey to consolidate the fragmented healthcare sector in Uganda and beyond. This initiative underscores the organization’s dedication to raising funds independently and leveraging its consolidated structure to drive significant improvements in healthcare access, quality, and efficiency across Africa.

“We are thrilled to be streamlining and developing our local operations, now bolstered by an independent legal framework fully aligned with Uganda’s legal system,” said Chairman Whitney Lynn, who has over 45 years of experience in the M&A sector expressed his enthusiasm for the strategic direction of XRP Healthcare and the incorporation of XRP Healthcare Africa, in Uganda.

“The establishment of a cohesive and autonomous entity in Uganda marks a significant milestone in our journey. I’m incredibly excited about the opportunity to reveal our plans and the progress we anticipate in Uganda. This move not only strengthens our commitment to the region but also sets the stage for a transformative impact on healthcare delivery across Africa.”

 

About XRP Healthcare

XRP Healthcare is the first Pharma and Healthcare platform on the XRP Ledger, enabling fast global payments, improving healthcare access in emerging markets, and creating realworld utility by transforming global healthcare through mergers, acquisitions and blockchain.

 

www.xrphealthcare.com

Photo – https://mma.prnewswire.com/media/2373918/XRP_Healthcare_1.jpg
Logo – https://mma.prnewswire.com/media/2365357/XRP_Healthcare_Logo.jpg

XRP Healthcare Logo

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/xrp-healthcare-move-forward-as-one-entity-for-african-ma-venture-302101765.html

Continue Reading

Trending